# Body composition's impact on MAFLD resolution: insights from bariatric surgery in an Eastern-Asian context

# <u>Ting-Wei Chang <sup>1,2\*</sup></u>, Ivy Ya-Wei Huang <sup>2,3</sup>, Ming-Lung Yu<sup>4,5</sup>, Chih-Kun Huang <sup>6</sup>, Po-Chih Chang<sup>1,2,7</sup>

1 Division of Thoracic Surgery, Department of Surgery, Kaohsiung Medical University Hospital/Kaohsiung Medical University, Kaohsiung City, Taiwan
2 Weight Management Center, Kaohsiung Medical University Hospital/Kaohsiung Medical University, Kaohsiung City, Taiwan
3 Department of Nursing, Kaohsiung Medical University Hospital/Kaohsiung Medical University, Kaohsiung City, Taiwan
4 Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
5 School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver. National Sun Yat-sen University, Kaohsiung, Taiwan.
6 Body Science and Metabolic Disorders International Medical Center, China Medical University Hospital, Taichung City, Taiwan
7 School of Medicine, College of Medicine, National Sun Yat-sen University

XXVII IFSO World Congress



#### CONFLICT OF INTEREST DISCLOSURE

In accordance with «EACCME criteria for the Accreditation of Live Educational Events», please disclose whether you have or not any conflict of interest with the companies:

#### If you don't have any conflict, please delete the conflict of interest report points:

#### [V] I have no potential conflict of interest to report

#### [] I have the following potential conflict(s) of interest to report:

- Type of affiliation / financial interest:
- Receipt of grants/research supports:
- Receipt of honoraria or consultation fees:
- Participation in a company sponsored speaker's bureau:
- Stock shareholder:
- Spouse/partner:
- Other support (please specify):

# XXVII IFSO World Congress



- Visceral fat is directly associated with liver inflammation and fibrosis independent of insulin resistance and hepatic steatosis.
- Visceral fat should therefore be a central target for future interventions in nonalcoholic steatohepatitis and indeed all metabolic disease.
- This study aims to investigate the potential influencing factor of body composition and MAFLD resolution.





van der Poorten D, *Hepatology*. 2008;48(2):449-457.

Liver-kidney contrast

**Bioelectrical Impedance Analysis** 

XXVII IFSO World Congress



- Our retrospective study analyzes patient data from an Asian center specializing in weight management, spanning <u>August 2016 to October 2023.</u>
- We examined <u>208 consecutive patients</u> who underwent bariatric procedures, including laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB), at our advanced medical facility.
- The study focused on <u>63 individuals</u> with severe obesity who were evaluated using abdominal ultrasound and body composition analysis one year following surgery. <u>(40 LSG and 23 LRYGB)</u>



Table1 Demographic				
	Total (n=63)	LSG (n=40)	LRYGB (n=23)	<i>P</i> value
Age (years)	$37.02 \pm 10.60$	$35.3 \pm 9.04$	$40 \pm 12.54$	0.124
Body height (cm)	$168.29 \pm 8.99$	$168.4 \pm 9.75$	$168.1 \pm 7.69$	0.901
Body weight (kg)	$120.24 \pm 24.52$	$113.70 \pm 20.01$	131.63 ± 27.76	0.004
BMI ( kg/m2)	$42.37 \pm 7.48$	39.94 ± 4.96	$46.60 \pm 9.20$	0.003
Preoperative body fat (%)	46.66 ± 7.15	$45.95 \pm 5.90$	$47.90 \pm 8.93$	0.354
Preoperative trunk fat (kg)	$24.20 \pm 4.30$	$23.62 \pm 3.99$	$25.20 \pm 4.72$	0.16
Preoperative visceral fat area (VFA)(cm <sup>2</sup> )		$227.02 \pm 30.96$	228.1 ± 43.34	0.909
Preoperative skeletal muscle mass	35.64 ± 7.67	34.58 ± 7.89	$37.48 \pm 7.08$	0.149
Body weight 12 months after surgery		84.11 ± 18.73	89.67 ± 15.08	0.238
Body fat 12 months after surgery(%)	$44 \times 17 \times 104$	$34.07 \pm 7.80$	33.36 ± 11.01	0.792
Trunk fat 12 months after surgery (kg)	$ 6.0  \pm  3.59 $	16.97 ± 16.55	$14.35 \pm 5.68$	0.476
VFA12 months after surgery (cm2)	$136.2 \pm 47.94$	133.98 ± 45.15	$140.04 \pm 53.31$	0.641
Skeletal muscle mass 12 months after surgery	$3130 \pm 750$	30.81 ± 8.36	$32.14 \pm 5.87$	0.514

	Fatty liver improved		Fatty liver resolution	
	F	P value	F	<i>P</i> value
Gender	1.766	0.164	1.134	0.291
Age	1.249	0.3	2.035	0.159
Body Weight	3.302	0.026	6.998	0.01
Preoperative diabetes mellitus	0.783	0.508	0.138	0.711
Preoperative body fat (%)	1.455	0.236	4.494	0.038
Preoperative trunk fat (kg)	3.799	0.015	10.669	0.002
Preoperative Visceral Fat Area (VFA) (cm2)	6.48	<.001	16.085	<.001
Preoperative skeletal muscle mass (kg)	1.051	0.377	1.034	0.313



	Univariate Regression Analysis		Multivariate Regression Analysis	
	95% CI	P value	95% CI	P value
Body Weight (kg)	0.002±0.012	0.011	-0.005±0.01	0.447
Preoperative Body fat(%)	0.001±0.036	0.038	-0.04±0.013	0.303
Preoperative trunk fat (kg)	0.017±0.073	0.002	-0.067±0.049	0.759
Preoperative Visceral Fat Area (VFA) (cm <sup>2</sup> )	0.003±0.01	<.001	0.002±0.015	0.016



- Our findings emphasize the critical role of visceral fat reduction in the remission of MAFLD following bariatric surgery in Eastern-Asian populations.
- The study confirms bariatric surgery's effectiveness in treating obesity-induced liver conditions and highlights the significance of targeting visceral adiposity.
- These results advocate for more research to develop tailored treatment strategies that improve MAFLD outcomes, thus enhancing the surgical management of liver diseases.



